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Abstract
Background: Cigarette smoking is the number one cause of preventable death among American Indian and
Alaska Natives, AI/ANs. Two out of every five AI/AN will die from tobacco-related diseases if the current smoking
rates of AI/ANs (40.8%) persist. Currently, there is no proven, effective culturally-tailored smoking cessation program
designed specifically for a heterogeneous population of AI.
The primary aim of this group randomized clinical trial is to test the efficacy of “All Nations Breath of Life” (ANBL)
program compared to a non-tailored “Current Best Practices” smoking cessation program among AI smokers.
Methods: We will randomize 56 groups (8 smokers per group) to the tailored program or non-tailored program
for a total sample size of 448 American Indian smokers. All participants in the proposed study will be offered
pharmacotherapy, regardless of group assignment. This study is the first controlled trial to examine the efficacy of
a culturally-tailored smoking cessation program for American Indians. If the intervention is successful, the potential
health impact is significant because the prevalence of smoking is the highest in this population.
Trial Registration: ClinicalTrials.gov: NCT01106456
Background
Although American Indian and Alaska Natives (AI/ANs)
make up approximately 1% of the US population, they
have the highest smoking rates of any racial/ethnic
group in the US [1]. Smoking rates among AI/AN smo-
kers vary by region and are highest in the Northern
Plains 44.1%, and lowest in the Southwest 21.2% [2,3].
AI/AN smokers have more difficulty quitting smoking
compared to other ethnic groups, [4] evidenced by their
significantly lower quit ratios [5,6], and are among the
least successful in maintaining long term abstinence.
Cigarette smoking is the number one cause of preven-
table death among AI/ANs [7,8]. The death rate among
AI/ANs due to tobacco use is double that of other
groups in the United States [8].
There are currently no proven, effective smoking cessa-
tion programs designed specifically for a heterogeneous
population of AI/AN. A few attempts at the tribal level
have proven effective and a few untested attempts have
been made for diverse groups. The “It’sY o u rL i f e-I t ’s
Our Future” project in Northern California used mes-
sages related to cultural identity, responsibility to family
and tribe, and respect for tobacco products [6]. The pro-
gram was tailored to the California AI/AN community
and had a 5.7% quit rate at 18-month follow-up for the
intervention group versus a 3.1% quit rate for the control
group. The Giving American Indians No-smoking Strate-
gies (GAINS) study was conducted to determine the fea-
sibility and effectiveness of delivering a smoking
cessation intervention through health clinics serving
urban AI/ANs sites in Seattle, Milwaukee, Minneapolis,
and Spokane [9]. A major goal was to implement a cultu-
rally appropriate adaptation of the Doctors Helping Smo-
kers (DHS) model [10]. The GAINS intervention
incorporated five major principles: (1) screening of
patients for smoking status, (2) use of smoke card as a
reminder to providers, (3) discussion of smoking cessa-
tion with a clinician, (4) supportive reinforcement by
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any medium, provided the original work is properly cited.clinic staff, and (5) monitoring of quit progress using the
smoke cards. The 7-day point prevalence abstinence
rates were not different between the intervention group
(6.7%) and the control group (6.8%) at one year follow-
up. Potential reasons for this null effect include: incom-
plete implementation, large proportion of subjects were
not exposed to the intervention, early problems with
delivery of the program by clinic staff, high non-response
rates, and a need for further cultural-targeting. No for-
mative research was conducted to determine acceptabil-
ity of the intervention to the target population.
The “Second Wind” smoking cessation curriculum
(developed by the Muscogee Nation in Oklahoma) is
based on the FreshStart curriculum created by the
American Cancer Society. It consists of six group ses-
sions, with groups meeting every two weeks for counsel-
ing and receipt of pharmacotherapy. Second Wind
utilizes the “Talking Circle” format, which is a familiar,
comfortable, and culturally acceptable tradition within
many AI/AN communities [11]. Historically, talking cir-
cles have been used by many tribes as a vehicle for dis-
cussing and presenting important issues relevant to all
members of the tribe. Although this program was
recently developed and disseminated to several tribes,
no data on its efficacy are available because no formal
evaluation to determine its impact on smoking cessation
was conducted. In summary, there is a lack of empiri-
cally validated programs for smoking cessation in the
AI/AN population and therefore, an urgent need for
programs such as the ANBL.
Current treatment guidelines recommend that beha-
vioral counseling and pharmacotherapy be offered to
any smoker interested in quitting [12]. A strong dose-
response relationship has been found between the
amount of personal contact with program staff and
smoking cessation. Four or more sessions are recom-
mended. Treatment by nurses, behavioral counselors,
physicians, and other clinician types are all effective.
Pharmacotherapy doubles quit rates when compared to
placebo [13], and the highest abstinence rates are
achieved when pharmacotherapy is combined with
counseling [14]. Our intervention provides pharma-
cotherapy to all participants and targeted counseling
delivered by AI counselors who have worked closely
with the American Indian communities and respect the
cultures, values, and traditions of the Indian people.
Therefore, our intervention includes the current “best
practice” recommendations for smoking cessation as
well as a culturally-tailored group counseling program.
There is much diversity in tobacco use among AI/ANs
throughout the country. Along with such plants as sage,
cedar, sweet grass, and red willow bark, tobacco has
long been a sacred plant for many AI/AN tribes [15].
Because tobacco was not native to all areas of the
United States, a number of AI/AN tribes did not use
it historically for ceremonial or spiritual purposes.
However, early use of tobacco in smoke offerings, pipe
smoking, burial services, gift-giving, and for medicinal
purposes is well-documented, particularly among tribes
native to the eastern seaboard and the Great Plains (e.g.
Six Nations of the Iroquois, [16] Delaware, Nanticoke,
[17] Lakota [18]). Many AI/AN people believe that
tobacco connects them to the spirit world through
prayer (e.g. Lenape) [19,20]. Tobacco is also used at
AI/AN ceremonies, such as a sweat lodge, Sun Dance,
or Yuwipi (e.g. Lakota) [21]. It is considered a gift from
the Creator (e.g. Absarokas and Hidatsa) [20]. Tradi-
tional tobacco use is common in the AI/AN population
and has diffused to many other AI/ANs who did not
historically use it, particularly at powwows, where it is
often given as a gift to the host drum [22]. When devel-
oping a smoking cessation program for a heterogeneous
population, such as the one in Kansas where over 200
different groups are represented, it is imperative to
acknowledge the diversity of traditional ritual and spiri-
tual use of tobacco. It is also important to differentiate
between traditional tobacco use and recreational smok-
ing and acknowledge that conventional tobacco control
messages that portray tobacco entirely negatively may
be offensive and hence ineffective in AI/AN commu-
nities [23].
There is a desperate need for effective, culturally tai-
lored cessation programs [24,25]. The primary aim of
this group randomized clinical trial is to test the efficacy
of “All Nations Breath of Life” (ANBL) program com-
pared to a non-tailored “Current Best Practices” smok-
ing cessation program among AI smokers.
Methods/Design
All Nations Breath of Life (ANBL) was developed using
the principles of community-based participatory
research [26] that include: 1) tailoring to meet the needs
of individuals and communities; and 2) providing the
opportunity for the people for whom the program is
developed to participate in the development, implemen-
tation, and evaluation. To address these principles and
to ensure that the program meets the needs of those it
is designed to help, we involve AI/AN community mem-
bers at all points of program development, allowing us
to tailor our program to the AI/AN population. We also
recognize that our target AI/AN population is not a
community defined by geopolitical borders, but by a
shared identity. This shared native identity, however, has
multiple manifestations that do not form one overarch-
ing culture (defined as a system of knowledge, beliefs,
values, morals and symbols, in terms of which human
groups interact among themselves, with other groups,
and with their natural environment) [27]. Ethnic identity
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others. In the case of many AI/AN, ethnic identity when
talking with a non-Native person is supra-tribal; in
other words, it is a shared identity of being AI/AN [28].
Culture is tribe-specific. The AI/AN designation is used
to describe a heterogeneous group of people by the U.S.
government. Because of this heterogeneity, tailoring
interventions to the community or “culture” becomes
exceedingly difficult. We address this heterogeneity
throughout our program by incorporating ideas and
practices from many AI/AN cultures.
In order to implement the ANBL program, we will use
AI facilitators for our group sessions. The program
includes interactions between individual smokers and
the facilitators, as well as group dynamics within each
cessation group. Group dynamics involve smokers’ inter-
actions with each other, as well as with the facilitator.
Our use of the talking circle format, as well as our use
of AI/AN facilitators, is designed to facilitate positive
group dynamics.
Design Overview
Figure 1 provides an overview of the study. This study
will use a group randomized multi-site clinical trial
design to examine the efficacy of a culturally-tailored
smoking cessation program (ANBL)f o rA I / A Ns m o k e r s
versus Non-tailored Current Best Practices (CBP).
AI/AN smokers in two sites (Kansas and Oklahoma) will
be group randomized to either ANBL or Non-tailored
(CBP). Each site (KS and OK) will randomize 28 groups,
resulting in 14 groups per arm of the intervention. Parti-
cipants in both groups (ANBL and CBP) will be offered
pharmacotherapy (e.g. varenicline or bupropion or NRT).
The primary outcome of interest will be biochemically
verified continuous abstinence at 1 year. Secondary end-
points include number of quit attempts and number of
cigarettes smoked (among continuing smokers), pharma-
cotherapy utilization, and the number of completed
group sessions. We will also examine the marginal cost-
effectiveness of the intervention.
The study will proceed in three phases over a five-year
period. Phase I will consist of development and training.
Phase 2 will be to conduct the randomized trial, and
Phase 3 consists of data analysis and dissemination.
Participants will be recruited from two sites: Kansas
and Oklahoma. Although the ANBL arm is a group
intervention and the CBP arm is individual standard
care, the unit of randomization will be at the group
level. Recruitment and randomization will be balanced
by site: both sites will recruit until we reach our target
sample size of 448 AI/AN smokers who are at least 18
years of age (see eligibility criteria in Table 1). Each site
will randomize 28 groups (14 groups per arm) with 8
smokers in each group for a total site sample size of 224
smokers per site.
Randomization Process
All participants who consent to participate will be rando-
mized to either the ANBL or CBP arm. Randomization
will be performed at each site after recruitment, the base-
line telephone assessment and determination of eligibility.
Participants will form temporal clusters in recruiting order
(i.e. the first 8 participants form cluster 1, the second 8
participants form cluster 2, and so on), and then pairs of
clusters will be assigned to the groups using randomized
permuted blocks based on a computer generated random
numbers to guarantee the balance between arms at each
site (Kansas and Oklahoma) [29]. For example at each site,
the first pair of clusters will be assigned to the ANBL and
the CBP groups, respectively, and the second pair of clus-
ters will be assigned to the CBP and the ANBL groups,
respectively. Thus, the main purpose of this allocation
scheme is to assure balance with respect to the number of
participants assigned to each arm of the trial in a logisti-
cally convenient fashion. This process continues until we
Kansas  Oklahoma 
x All Participants will be offered free pharmacotherapy  
x (Varenicline or Bupropion or NRT) 
x Cluster or group size is 8 smokers per group.   
x Each site (Kansas and Oklahoma) will randomize 28 groups, 
resulting in 14 groups per arm of the intervention, per site. 
x Total sample size per site is 224 smokers 
Total Participants (N) = 448
ANBL 
N=112 
Non-Tailored 
N=112  
Non-tailored 
N=112  
28 Groups  28 Groups 
ANBL 
N=112 
Figure 1 Design of Randomized Clinical Trial of Smoking
Cessation among American Indians.
Table 1 Eligibility Criteria for Participants
Eligibility criteria
Inclusion Criteria Exclusion Criteria
Age 18 years or older
Have a home address and
telephone number
Willing to participate in all
study components
Willing to be followed-up
for 12 months
Smoked at least 100
cigarettes in their lifetime
Current smoker
American Indian or Alaska
Native (self-identified)
Planning to leave the state within next
24 months
Pregnant or breast feeding or planning
to become pregnant in next 4 months.
Medically ineligible after screening
Choi et al. Trials 2011, 12:126
http://www.trialsjournal.com/content/12/1/126
Page 3 of 10end up with 14 clusters in the ANBL arm and 14 clusters
in the CBP arm at each site. Facilitators will be responsible
for delivering the interventions and separate assessors will
be responsible for conducting assessments.
All Nations Breath of Life (ANBL) Intervention
Components
The current version of ANBL has five primary compo-
nents, designed by our pilot participants and research
team members, These are: (1) group support sessions,
(2) individual telephone counseling using Motivational
Interviewing (MI), (3) a culturally tailored educational
curriculum, (4) pharmacotherapy, and (5) participant
incentives, all of which have been tailored specifically to
a heterogeneous group of AI/AN people.
Group Support Sessions
During our initial discussions with community members
about what they would like to see in a smoking cessa-
tion program, nearly everyone wanted group support led
by a community member. Therefore, the primary com-
ponent of ANBL is a series of group-based support ses-
sions. We discussed who would lead the sessions at
length, particularly whether they needed to be trained
counselors or have certain educational degrees. We
decided the most important factor when choosing indi-
viduals to lead the groups was their ties to the AI/AN
community. Due to low rates of educational attainment
in the AI/AN community, we decided it would be best
to not limit session leaders to individuals with counsel-
ing degrees and/or experience. Instead we decided to
train community members in group support and coun-
seling skills. We also decided not to call our group
leaders “counselors” d u et oar e t i c e n c eo nt h ep a r to f
community members to trust providers trained in
Western counseling techniques. In addition, the term
“counselor” implies the group leader is above group
members and is the most qualified to give advice. We
chose the term “facilitator” because we see this role as
facilitating discussion and creating positive group
interaction. The group members themselves provide
the majority of support and advice, with help from
the facilitator and educational materials. We have
been lucky to find community members with social
work or psychology backgrounds willing to help
develop methods for group building and support facil-
itation. All group sessions begin with team building
exercises and personal discussion among members
about things they might be experiencing in their lives,
both those related directly to smoking and other
things that may come up that help or hinder quit
attempts. Our first group session is devoted largely to
forming a cohesive group and learning all members’
personal stories about their life-long journeys with
tobacco, both sacred and recreational.
Individual Telephone Counseling
Our participants and community partners have stressed
the need for some individual counseling, particularly for
people who are uncomfortable talking about certain
things in our mixed-gender, mixed-age, mixed-tribe
groups. Therefore, our most recent incarnation of
ANBL includes telephone calls that go beyond a remin-
der about the next group session (the original purpose
of the calls). Between group sessions, facilitators call
participants to see how they are doing, provide counsel-
ing for personal issues, and to remind them of the next
group session. Facilitators also ask about side effects of
medication and any adverse events. During these calls,
facilitators will use Motivational Interviewing (MI),
which has been found to be effective among AI/AN
[30]. MI is designed to enhance motivation for change,
and is based on the assumption that many individuals
with addictions are not in an advanced state of readiness
to change. The goal of MI is to increase an individual’s
motivation to change by developing a discrepancy
between current behavior and goals and/or values.
Educational Curriculum
Our educational curriculum is divided into 11 bro-
chures, given throughout the program, and combines
the latest smoking cessation methods with culturally-
specific elements. Community members have stressed
throughout development of the program that cultural
issues must be ingrained within the program and its
accompanying education materials, not given “lip ser-
vice” by putting pictures of AI/AN people on otherwise
“White” materials. Our materials have evolved through
several iterations over time [31-34]. Our current materi-
als were created by our research team and Community
Advisory Board (CAB) members, with input from pilot
participants, and then sent to an AI/AN graphic artist
(Nakota Designs, Inc.), for final layout.
Pharmacotherapy Offered to All Participants
Current treatment guidelines recommend pharma-
cotherapy be offered to all smokers making a quit
attempt. The PI and site PI of this study along with our
AI/AN community members agreed that all participants
(ANBL and CBP arms) had to be offered pharmacother-
apy (varenicline or bupropion or NRT) as a component
of the study design. This decision was a collaborative
one between the AI/AN tribes and the investigators who
have worked with this population. The AI/AN commu-
nity will not accept placebo treatment, therefore, the
interventions would not be acceptable or feasible to
potential participants if a placebo was part of the study
design. In addition, we believed it was ethically impera-
tive that we provide smoking cessation interventions
consistent with the current clinical practice guidelines
for the treatment of tobacco use. Consequently, we
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cotherapy, including Chantix
®,Z y b a n
®, Nicotine Repla-
cement Therapy (NRT, patches, gum, or lozenges), or a
combination of the latter two. Participants can also
choose no pharmacotherapy. All facilitators are trained
in providing advice and addressing questions related to
pharmacotherapy and discuss the options with partici-
pants, also asking about medical history to determine if
there is any reason the individual should not be taking
medication. Participants are also given educational bro-
chures about the options and have the option of talking
with a physician privately. All participants requesting
prescription medication must be medically cleared prior
to receiving medication. Study staff ensure that provi-
ders in the area are informed about the study prior to
recruitment, and work with participants and providers
to ensure that smokers wanting prescription pharma-
cotherapy receive it expeditiously. As all forms of NRT
are over-the-counter medications, participants are not
required to obtain physician clearance to take them;
however, they receive written information about them
and facilitators explain risks.
Participant Incentives
Incentives were designed by our AI/AN research team
members and our CAB. Every week, participants receive
a “quit kit”, a variety of hard candy, gum, flavored tooth-
picks, straws, American Indian snacks, etc., to help them
avoid smoking. Quit kits have been used successfully in
our pilot study, as well as in multiple other smoking
cessation programs [29,30]. Participants are given a
stress ball as a part of their initial quit kit, as well as a
magnet with a hole cut in the center to put a picture.
The magnets say “I want to quit smoking for...” and par-
ticipants can put a picture of themselves or someone
they care about. The idea for magnets came from parti-
cipants who talked about quitting for family members,
especially grandchildren. For the session devoted to tra-
ditional tobacco use, we originally had tribal elders
come in and talk about personal experience. However,
our participants felt it would be more appropriate to
talk amongst themselves and show a video of elders
talking about traditional use in different tribes. We have
since filmed several elders and are creating a video to
watch during the session andg i v ea sa ni n c e n t i v e .
When discussing stress management techniques, empha-
sis is placed on traditional activities and participants are
led through a stress reduction activity that uses Native
flute music. We have worked with two local flute players
to purchase copyrights to their music to develop CD’s.
To complement discussion of weight management, we
provide a copy of the DVD Rez-robics
®,as e to ft w o
aerobic videos that incorporate traditional dance. In an
earlier version of ANBL, participants were provided with
food during three group sessions, healthy snacks for
weight maintenance, a meal with a family member or
friend for social support, and a celebratory meal at the
final regular group session. After discussions with our
CAB, we decided that all of these meals/snacks will
become potluck, with participants and facilitators bring-
ing in food. This decision was made to help the sustain-
ability of the program in the real world. The fact that
KUMC owns the copyright to the DVD and flute music
CD adds to our sustainability because the only cost
involved in them is $1 per copy. Rez-robics
® may be
distributed free of charge to any AI/AN person.
At the Week 1 individual session and week 12 group
and month 6 group sessions, we provide a $20 gift card
for their time. All participants receive the gift cards for
their time, regardless of smoking status and willingness
to provide saliva for verification. Detailed descriptions of
session topics and incentives are shown in Table 2.
Session procedures and time commitment
Screening: Telephone Intake
The majority of intake interviews is conducted via tele-
phone, but may be done in person at any program site.
The initial screening reviews inclusion/exclusion criteria,
personal smoking levels and readiness to quit, and basic
information about the program. We estimate intake to
take 10-15 minutes. It is done by research assistants for
each program site or facilitators.
Individual In-person Meeting with Facilitator
Potential participants meet with their group facilitator
individually prior to the first group session. Individual
meetings allow facilitators to meet participants and form
a working relationship with them individually, thus help-
ing all participants feel more comfortable in the group
setting for the first session. They also allow facilitators
to fully explain the program and answer any questions
the participant may have that he or she may consider
“silly” or inappropriate to ask in front of a group and
allow full consenting of the individual privately. Indivi-
duals who consent to participate are enrolled in the pro-
gram and remain in the same group throughout the
program with the same facilitator for both group and
individual sessions. After enrolling in the program, par-
ticipants are asked to fill out a survey and asked to
allow the facilitator to take height, weight, and saliva
sample for baseline measurement of salivary cotinine.
Participants are asked to let their group facilitator know
what their choice of medication at the in-person session.
Facilitators answer any questions the participant has and
participants are given the option of having the study
physician call them to discuss personal concerns. Esti-
mated time for individual session is 50-60 minutes.
Group facilitators call all participants 1-2 days prior to
the group session as a reminder. All participants
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cation. The study physician reviews all medical informa-
tion prior to the first group session. Participants who do
not meet medical eligibility for their choice of medica-
tion are called by the study physician to discuss options.
Participants are reimbursed with a $20 gift card for
their time.
Group Session 1
T h ef i r s tg r o u ps e s s i o ni st h eq u i td a t ef o ra l lp a r t i c i -
pants in the group. By using one quit date, we ensure
that participants are going through the quitting process
together. As participants arrive, they are be asked to
complete weekly surveys. Study medication is provided
to participants at the group sessions, enough pills to last
Table 2 Flow of Participants for ANBL
Week # Type of Session Topics Covered Brochures/Other Handouts Incentives
Screening Telephone Intake Current smoking levels
Level of traditional/ceremonial use
Readiness to quit
None None
1 Individual in-person
meeting with
facilitator
Program start date
Quit date information
Questions about program
Personal history with smoking
NRT
Pharmacotherapy
Preparing to Quit
Cigarette smoking and Native
People
Tote bag and Binder for
educational materials
Photo magnet
ANBL pen
$20 gift card
Pharmacotherapy
2 Group in-person Personal histories with smoking
Team building
Social support I
Coping with withdrawal
Why people smoke
Quit Contract
Quit reasons card
Quit kits
Pharmacotherapy
Water bottles
3 Group in-person Discussion of current personal issues with
quitting or other
Facts about smoking
Things instead card Quit kit refills
Pharmacotherapy
ANBL bracelet
4 Group in-person Traditional use of tobacco
Discussion of current personal issues with
quitting or other
Traditional use of tobacco Quit kit refills
Pharmacotherapy
Traditional Use DVD
5 Group in-person Stress management
Discussion of current personal issues with
quitting or other
Stress reduction and
management
American Indian flute music
Meditation techniques
Quit kit refills
Pharmacotherapy
Flute music CD
Stress balls
6 Group in-person Weight management
Healthy eating and exercise
Discussion of current personal issues with
quitting or other
Reservation based aerobic exercise
techniques
Weight management during
smoking cessation
Discussion of Healthy American
foods (Healthy eating at
Powwows)
Quit kit refills
Pharmacotherapy
Rez-robics DVD or VHS
Pedometers
Healthy snacks
7 Group in-person Social support II
Discussion of current personal issues with
quitting or other
Friends and family and quitting
smoking
Quit kit refills
Pharmacotherapy
Meal with family
member/friend
8 Group in-person Staying quit
Discussion of current personal issues with
quitting or other
Staying quit Quit kit refills
Pharmacotherapy
ANBL T-shirt
9 Telephone MI Personal issues None None
10 Telephone MI Personal issues None None
11 Telephone MI Personal issues None None
12 Group in-person Celebration
Discussion of how traditional worldview
and behaviors helped in the quitting
process
Feedback on program
None Certificate of
Achievement Celebratory
potluck meal
$20 gift card
1 week prior to 6
months follow-up
Telephone MI Personal issues
Reminder to return to 6 month follow-up
None None
6-month Group in-person Current smoking status
Personal issues
None $20 gift card
12-Month Individual in-person Current smoking status None $20 gift card
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is available to answer additional questions. Beginning
with this session and continuing through all sessions,
facilitators start the session with a prayer (if the group
chooses to do so) and team building exercises. All dis-
cussions begin with each individual’s discussion of his
or her journey with tobacco and issues surrounding quit-
ting. Individual facilitators decide how to ensure all parti-
cipants who want to talk get a chance at each session.
After personal discussion, the topic(s) for the session is
discussed, using the associated educational materials (see
Table 2for topics and educational materials). Estimated
time for the group session is 60-90 minutes. During the
week between the group sessions, facilitators call partici-
pants to see how they are doing, provide counseling for
personal issues, and to remind them of the next group ses-
sion. Facilitators also ask about possible side effects of
medication and any adverse events. Estimated time for
each phone call is 15-20 minutes; though in our pilot
groups some calls went as long as 30 minutes.
Group Sessions 2-7
Weekly session and telephone procedures follow the
same format as for the first session. For discussion of
traditional tobacco, participants are asked to bring any
personal items surrounding the use of traditional
tobacco. During that session, participants decide as a
group if they would like to conduct a group ceremony
signifying their journey with ending recreational use of
tobacco and celebrating it as a sacred plant. Facilitators
are sure to acknowledge the diversity of tobacco use (or
nonuse) and adjust discussion and ceremony as appro-
priate. Participants watch the ANBL traditional tobacco
video during the session and are asked to share personal
stories if they choose.
Weeks 9-11
Participants receive one phone call per week from their
facilitator. Calls follow the same procedures as those
made in between group sessions.
Group Session (Week 12): End of Pharmacotherapy
Session discussion procedures follow the same format as
for other group sessions. Participants who have remained
abstinent provide saliva samples for cotinine analysis.
Participants and facilitators bring food for a potluck din-
ner. Participants are reimbursed with a $20 gift card for
their time. All participants, regardless of smoking status
receive a certificate of achievement for completing the
program. Estimated time is 60-90 minutes.
6-Month Follow-Up
At 6-months post-baseline, participants are asked to
return for a final group session. Participants self-reporting
continuous abstinence are asked to participate in salivary
cotinine analysis for verification. Participants are reim-
bursed with a $20 gift card for their time. Estimated time
is 60-90 minutes.
12-Month Follow-Up
At 12 months post-baseline, participants are asked to
return for a final individual session. After initial assess-
ment and collection of saliva sample (for those reporting
continuous abstinence) and smoking status, they are
asked to participate in a focus group about the program
itself and how to improve it. Procedures for the focus
group are discussed in Process Measures and Evaluation.
Participants are reimbursed with a $20 gift card for their
time. Estimated time is 30 minutes.
Non-Tailored - Current Best Practices (CBP) Intervention
Components
In this condition, non-Native facilitators follow a
detailed script and use a guide (American Cancer
Society) to provide education about the risks of smoking
and how to quit. The initial telephone sessions reviews
the health risks associated with smoking, the addictive
nature of tobacco, and the disproportionate effects of
tobacco. In addition, the facilitator and participant com-
plete the exercises on making a plan to quit, which
includes setting a quit date, and identifying a plan to
use the pharmacotherapy. They also list smoking related
habits and replacement activities. Towards the end of
the session, participants are asked to restate what was
agreed upon, and a verbal contract (i.e., pledge) is
secured. The follow-up sessions include an assessment
of progress towards meeting the quit goal, reviewing
educational information, completing exercises from the
guide (coping with urges; what to do in case of relapse,
resetting goals, and securing additional contracts. Facili-
tators will be trained (and monitored for compliance) to
avoid cultural-tailoring and maintaining protocol.
This counseling approach amounts to a fairly intensive
education-based intervention. It incorporates the recom-
mendations of current treatment guidelines which
include giving clear advice to quit, providing assistance
for quitting, and arranging follow-up. Health Education
is designed to give participants additional information
(such as health risks associated with smoking) and set
specific goals related to smoking (e.g., a quit date).
Health Education is characterized by providing informa-
tion and advice, which results in the educator talking
more than the participant. We also conduct on-going
monitoring, using audiotapes of sessions, to prevent
treatment contamination and to verify treatment fidelity.
Participants randomized to this arm are also all offered
pharmacotherapy (e.g. varenicline or bupropion or NRT).
In addition, they meet individually with a non-Native facil-
itator at weeks 1, 12 and 24 and 1-year for assessments,
collection of saliva, and coordination of pharmacotherapy.
Participants in this arm are provided 5 telephone sessions.
These calls are delivered near their quit date and each
individual call session is approximately 10 minutes.
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materials that are provided at the first individual session
are non-tailored cessation information. Facilitators pro-
vide participants with a brief brochure of current prac-
tice guidelines for smoking cessation.
Statistical Analyses/Sample Size and Power Calculations
Sample Size and Power
The primary endpoint is cotinine verified continuous
abstinence at 12 months. We expect a 30% cessation
rate in the ANBL group and a 15% cessation rate in
the CBP group. Based on the two-sample test for the
difference in proportions using un-pooled normal
approximation adjusted for variance inflation due to
intra-cluster correlation [35], along with the assump-
tions above and cluster size of 5 people and a very
conservative estimate of intra cluster correlation coeffi-
cient of 0.1 due to lack of relevant data (hence infla-
tion factor is 1.4), we will need 27 clusters in each arm
to have 80% power to conclude the cessation rate of
smokers who receive the ANBL counseling is higher
than that of those who receive non-tailored counseling
at 5% significance level (1-sided). To make the design
balanced in both sites, we will have 14 clusters in each
arm at each site, i.e. 28 clusters in each arm. Hence,
we will need a total of 56 clusters (14 clusters/arm/site
× 2 arms × 2 sites). Considering a conservative esti-
mate of attrition rate of 30%, we propose to recruit 8
people for each cluster, resulting in a total of 56 × 8 =
448 AI/AN smokers.
Statistical Analyses
Baseline Summary
We will first summarize all baseline characteristics glob-
ally and by treatment group. Categorical variables will
be summarized by frequencies and percentages and
quantitative variables will be summarized by means and
standard deviations.
Hypothesis Testing
In order to take into account the intracluster correla-
tion, the general estimation equations (GEE) will be
applied to hypothesis testing on comparing the interven-
tion effect at the individual-level for both the primary
and secondary aims (see below) using SAS PROC GEN-
MOD. We will examine correlation structures such as
the exchangeable and the first-order autoregressive or
the spatial-power, and determine the optimal structure
based on the Akaike Information Criterion (AIC). In
addition, for the exploratory purpose, we will also assess
potential covariates and mediating factors including
demographic, smoking history, psychological, and socio-
cultural factors that may contribute to smoking absti-
nence. Interaction effects among these factors will also
be assessed.
Primary Aim
1. To test the efficacy of All Nations Breath of Life Pro-
gram (ANBL) versus CBP on smoking cessation among
AI/AN smokers.
We will compare the salivary cotinine verified contin-
uous abstinence rates at 12 months (and at Week 12 in
a secondary aim, see below) between the two groups
using GEE. For our primary comparison, we will con-
duct comparisons using (i) only the participants who
complete the study, (ii) all subjects by imputing the
dropouts as smokers, and (iii) all subjects by multiple
imputation assuming the dropout mechanism to be
missing at random. In (iii), the imputation model will
match the model for data analysis as suggested by Alli-
son (2001).
To evaluate secondary endpoints, we will compare the
salivary cotinine verified continuous abstinence rates
b e t w e e ng r o u p sa tW e e k1 2( e n do fp h a r m a c o t h e r a p y ) .
Finally, as we have no preliminary estimates of relapse
based upon timeline follow-back, this will be an explora-
tory endpoint. We will compare the time to relapse
between the two groups using the frailty models (the
modified Cox regression models for correlated time to
relapse) to adjust for intracluster correlation.
Cost-effectiveness analysis The purpose of our cost-
effectiveness analysis is to establish the cost-effectiveness
of the ABNL program relative to standard care for
smoking cessation. While our cost analytic framework
follows the guidelines adopted by the CDC [36], we will
assess costs from the service provider perspective rather
than the recommended societal perspective. Given that
there is widespread agreement that the cessation of
smoking behavior confers important societal benefits
valued far in excess of the costs needed to produce
them, the research expenses needed to fulfill the societal
perspective would exceed the benefit of that approach.
Variable costs for each study arm will be valued in the
year during which they are incurred. Discounting is not
required for the six month intervention period, and
research costs ($20 gift cards) will be excluded from
analyses.
Program costs that will vary depending on the number
of participants include personnel time, phone charges,
materials (brochures and other handouts), pharma-
cotherapy, and participant incentives. Facilitator time for
group sessions and individual telephone counseling will
be documented using a time diary/log and valued at
wage rates including benefits. Phone charges for local
and long distance calls will be applied to the time for
telephone-based counseling. Costs to produce brochures
and other handouts will be tracked as they are printed.
Pharmacotherapy costs will be valued according to IHS
medication costs inclusive of dispensing fees. For sensi-
tivity analyses, we will vary pharmacotherapy costs
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the average of no fewer than three price sources (local
pharmacy as well as on-line pharmacy options). Mailing
costs will be added if appropriate. In addition, time for
physician prescribing and medication counseling as well
as pharmacist counseling will be included for the project
physician and project pharmacist (valued at wages plus
benefits). Items included as incentives (quit kits, stress
balls, photo magnets, water bottles, pens, bracelets, t-
shirts) will be valued at their retail prices. Videos and
CDs each cost $1 under the KUMC license, and the
Rez-robics DVDs will not be included as they are avail-
able for free.
Incremental Cost Analyses
We will report an incremental cost-effectiveness ratio
for the two arms. Incremental cost analyses identify the
marginal benefit of switching from one intervention to
the other relative to the increased cost. Since we
hypothesize that ABNL will be more effective and more
costly, the incremental cost-effectiveness analysis will
inform us as to whether the additional costs associated
with ABNL produce an acceptable level of benefit.
The effectiveness measure is the biochemically-veri-
fied, 7-day quit rate at 12 months.
In the event that pharmacotherapy costs make CBP
more expensive than ABNL, then the ICER will be
adjusted according with consideration of relative
effectiveness.
Sensitivity Analyses
All cost analyses invariably require certain assumptions.
The data derived for this cost analysis come from a clin-
ical trial based in Kansas and Oklahoma, so extrapola-
tion of the cost analysis requires adjustment of wage
rates. For instance, health care related wages in Kansas
are 86.0% of the national average [37]. Therefore, in sen-
sitivity analyses, we will adjust wages rates upwards to a
national average.
Likewise, the generalizability of a single clinical trial
result to other populations necessitates that we explore
how the variation in counseling time and effectiveness
influence the relative cost-effectiveness of the treatment
strategies. In the sensitivity analysis, we will vary these
measures +/- 2 standard deviations.
Summary
Currently, very few culturally-tailored smoking cessation
studies are carried out in the American Indian popula-
tion. The results from this randomized clinical trial will
contribute to the limited information on effective smok-
ing cessation programs for American Indian smokers.
American Indians have the highest rates of smoking pre-
valence of any racial/ethnic group in the US, and hope-
fully, the findings from this study will ultimately help
reduce the smoking-related health disparities in this
underserved population.
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